# A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

> **NCT04227275** · PHASE1 · TERMINATED · sponsor: **Tceleron Therapeutics, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **BIOLOGICAL:** CART-PSMA-TGFβRDN
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Anakinra

## Key facts

- **NCT ID:** NCT04227275
- **Lead sponsor:** Tceleron Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-11-22
- **Primary completion:** 2022-11-07
- **Final completion:** 2022-11-07
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Based on the safety events and evidence of biologic activity without sustained clinical responses the Sponsor finds the risk/benefit analysis unfavorable for patients and has terminated the study.
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04227275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04227275, "A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04227275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*